Drug Profile
Research programme: acetylcholinesterase - Protalix Biotherapeutics
Alternative Names: AChE programme - Protalix BiotherapeuticsLatest Information Update: 12 Mar 2012
Price :
$50
*
At a glance
- Originator Boyce Thompson Institute for Plant Research; Hebrew University of Jerusalem
- Developer Protalix Biotherapeutics
- Class Antitoxins; Recombinant proteins
- Mechanism of Action Cholinesterase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Poisoning
Most Recent Events
- 07 Mar 2012 No development reported - Preclinical for Poisoning in Israel (Parenteral)
- 22 Jan 2008 Protalix Biotherapeutics extends its research agreement with Yissum Research Development Company to include a collaborative research programme at the Hebrew University of Jerusalem
- 22 Jan 2008 Preclinical trials in Poisoning in Israel (unspecified route)